$BNGO
Bionano Genomics, Inc. Stock $bngo

$bngo Overview Financials Valuation SEC Filings Company Website

2020 Q1 Form 10-Q Financial Statement

#000141169020000011 Filed on June 18, 2020

Income Statement

Concept	2020 Q1	2019 Q1
Revenue	$1.136M	$1.853M
YoY Change	-38.69%	4.78%
Cost Of Revenue	$856.0K	$1.147M
YoY Change	-25.37%	36.31%
Gross Profit	$280.0K	$706.0K
YoY Change	-60.34%	-23.84%
Gross Profit Margin	24.65%	38.1%
Selling, General & Admin	$7.368M	$4.791M
YoY Change	53.79%	65.47%
% of Gross Profit	2631.43%	678.61%
Research & Development	$2.674M	$2.100M
YoY Change	27.33%	-11.28%
% of Gross Profit	955.0%	297.45%
Depreciation & Amortization	$296.0K	$270.0K
YoY Change	9.63%	-31.03%
% of Gross Profit	105.71%	38.24%
Operating Expenses	$10.04M	$6.891M
YoY Change	45.73%	30.95%
Operating Profit	-$9.762M	-$6.185M
YoY Change	57.83%	42.66%
Interest Expense	$761.0K	$273.0K
YoY Change	178.75%	-9.6%
% of Operating Profit
Other Income/Expense, Net	-$743.0K	-$1.662M
YoY Change	-55.29%	-437.89%
Pretax Income	-$10.51M	-$7.847M
YoY Change	33.87%	104.16%
Income Tax	$5.000K	$5.000K
% Of Pretax Income
Net Earnings	-$10.51M	-$7.852M
YoY Change	33.85%	104.09%
Net Earnings / Revenue	-925.18%	-423.75%
Basic Earnings Per Share
Diluted Earnings Per Share	-$295.5K	-$768.9K
COMMON SHARES
Basic Shares Outstanding	37.75M shares	10.10M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2020 Q1	2019 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$8.100M	$20.80M
YoY Change	-61.06%	173.68%
Cash & Equivalents	$8.144M	$20.83M
Short-Term Investments
Other Short-Term Assets	$1.100M	$1.374M
YoY Change	-19.94%	-19.18%
Inventory	$3.611M	$1.406M
Prepaid Expenses
Receivables	$4.115M	$4.057M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$16.98M	$28.01M
YoY Change	-39.38%	103.0%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.120M	$1.537M
YoY Change	37.92%	-40.88%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$2.120M	$1.537M
YoY Change	37.92%	-43.07%
TOTAL ASSETS
Total Short-Term Assets	$16.98M	$28.01M
Total Long-Term Assets	$2.120M	$1.537M
Total Assets	$19.10M	$29.55M
YoY Change	-35.36%	79.1%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.176M	$870.8K
YoY Change	264.71%	-3.24%
Accrued Expenses	$2.725M	$3.629M
YoY Change	-24.91%	29.6%
Deferred Revenue	$318.0K
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change		-100.0%
Long-Term Debt Due	$16.97M
YoY Change
Total Short-Term Liabilities	$23.19M	$4.714M
YoY Change	391.95%	-82.48%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$18.38M
YoY Change	-100.0%
Other Long-Term Liabilities	$0.00	$287.3K
YoY Change	-100.0%	-52.11%
Total Long-Term Liabilities	$0.00	$18.66M
YoY Change	-100.0%	3010.52%
TOTAL LIABILITIES
Total Short-Term Liabilities	$23.19M	$4.714M
Total Long-Term Liabilities	$0.00	$18.66M
Total Liabilities	$23.32M	$23.68M
YoY Change	-1.55%	-13.89%
SHAREHOLDERS EQUITY
Retained Earnings	-$113.1M	-$80.61M
YoY Change	40.28%
Common Stock	$108.9M	$86.48M
YoY Change	25.89%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$4.213M	$5.870M
YoY Change
Total Liabilities & Shareholders Equity	$19.10M	$29.55M
YoY Change	-35.36%	79.1%

Cashflow Statement

Concept	2020 Q1	2019 Q1
OPERATING ACTIVITIES
Net Income	-$10.51M	-$7.852M
YoY Change	33.85%	104.09%
Depreciation, Depletion And Amortization	$296.0K	$270.0K
YoY Change	9.63%	-31.03%
Cash From Operating Activities	-$8.032M	-$6.552M
YoY Change	22.59%	-3.47%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$0.00
YoY Change		-100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	$0.00	$0.00
YoY Change		-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$0.00	$2.410M
YoY Change	-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$1.135M	$10.86M
YoY Change	-110.45%	-18.54%
NET CHANGE
Cash From Operating Activities	-$8.032M	-$6.552M
Cash From Investing Activities	$0.00	$0.00
Cash From Financing Activities	-$1.135M	$10.86M
Net Change In Cash	-$9.167M	$4.307M
YoY Change	-312.84%	-34.05%
FREE CASH FLOW
Cash From Operating Activities	-$8.032M	-$6.552M
Capital Expenditures	$0.00	$0.00
Free Cash Flow	-$8.032M	-$6.552M
YoY Change	22.59%	-3.64%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2019Q4	bngo	Adjustmentsto Additional Paidin Capital Reduction In Warrant Exercise Price For Covenant Waiver AdjustmentstoAdditionalPaidinCapitalReductionInWarrantExercisePriceForCovenantWaiver	46000	USD
CY2019Q1	bngo	Fair Value Of Stock Issued With Debt Classified As Liability FairValueOfStockIssuedWithDebtClassifiedAsLiability	202000	USD
CY2020Q1	bngo	Fair Value Of Stock Issued With Debt Classified As Liability FairValueOfStockIssuedWithDebtClassifiedAsLiability	0	USD
CY2019Q1	bngo	Fair Value Of Warrants Issued With Debt Classified As Liability FairValueOfWarrantsIssuedWithDebtClassifiedAsLiability	630000	USD
CY2020Q1	bngo	Fair Value Of Warrants Issued With Debt Classified As Liability FairValueOfWarrantsIssuedWithDebtClassifiedAsLiability	0	USD
CY2019Q4	bngo	Stock Issued During Period Value Covenant Waiver StockIssuedDuringPeriodValueCovenantWaiver	504000	USD
CY2019Q4	bngo	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	9397000	USD
CY2020Q1	bngo	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	2355000	USD
CY2019Q1	bngo	Transfer Of Instruments To Property And Equipment From Inventory TransferOfInstrumentsToPropertyAndEquipmentFromInventory	0	USD
CY2020Q1	bngo	Transfer Of Instruments To Property And Equipment From Inventory TransferOfInstrumentsToPropertyAndEquipmentFromInventory	467000	USD
CY2020Q1	dei	Amendment Flag AmendmentFlag	false
CY2020Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2020Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2020Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
CY2020Q1	dei	Document Period End Date DocumentPeriodEndDate	2020-03-31
CY2020Q1	dei	Document Type DocumentType	10-Q
CY2020Q1	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2020Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001411690
CY2020Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	83915045	shares
CY2020Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2020Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2020Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2020Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2020Q1	dei	Entity Registrant Name EntityRegistrantName	Bionano Genomics, Inc.
CY2020Q1	dei	Entity Shell Company EntityShellCompany	false
CY2020Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2699000	USD
CY2020Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	3176000	USD
CY2019Q4	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	6889000	USD
CY2020Q1	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	5628000	USD
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	6334000	USD
CY2020Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	4115000	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3225000	USD
CY2020Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2725000	USD
CY2019Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	106188000	USD
CY2020Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	108871000	USD
CY2019Q1	us-gaap	Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	202000	USD
CY2019Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	289000	USD
CY2019Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	336000	USD
CY2019Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	364000	USD
CY2019Q4	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	357000	USD
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	328000	USD
CY2019Q1	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	630000	USD
CY2019Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	289000	USD
CY2020Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	328000	USD
CY2019Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	555000	USD
CY2020Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	1513000	USD
CY2019Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5932000	shares
CY2020Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	26888000	shares
CY2019Q4	us-gaap	Assets Assets	30208000	USD
CY2020Q1	us-gaap	Assets Assets	19102000	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	28258000	USD
CY2020Q1	us-gaap	Assets Current AssetsCurrent	16982000	USD
CY2019Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	30000	USD
CY2020Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	17311000	USD
CY2020Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8100000	USD
CY2020Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8144000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	16523000	USD
CY2019Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	20830000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	17311000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	8144000	USD
CY2019Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	4307000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-9167000	USD
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.77
CY2020Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1261000	USD
CY2019Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	551000	USD
CY2020Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2020Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2020Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	34274000	shares
CY2020Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	37752000	shares
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	34274000	shares
CY2020Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	37752000	shares
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	3000	USD
CY2020Q1	us-gaap	Common Stock Value CommonStockValue	3000	USD
CY2019Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	358000	USD
CY2020Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	318000	USD
CY2019Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	183000	USD
CY2020Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	127000	USD
CY2019Q1	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	89000	USD
CY2020Q1	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	127000	USD
CY2019Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1147000	USD
CY2020Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	856000	USD
CY2019Q1	us-gaap	Costs And Expenses CostsAndExpenses	6891000	USD
CY2020Q1	us-gaap	Costs And Expenses CostsAndExpenses	10042000	USD
CY2019Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	21971000	USD
CY2020Q1	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	18625000	USD
CY2019Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	1886000	USD
CY2020Q1	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	1656000	USD
CY2019Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	270000	USD
CY2020Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	296000	USD
CY2020Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.30
CY2019Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-1333000	USD
CY2020Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2019Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-7847000	USD
CY2020Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-10505000	USD
CY2019Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	5000	USD
CY2020Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	5000	USD
CY2019Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-511000	USD
CY2020Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	477000	USD
CY2019Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-457000	USD
CY2020Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-639000	USD
CY2019Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	337000	USD
CY2020Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	635000	USD
CY2019Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	801000	USD
CY2020Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-53000	USD
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	-6398000	USD
CY2019Q4	us-gaap	Net Income Loss NetIncomeLoss	-7900000	USD
CY2019Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-56000	USD
CY2020Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	18000	USD
CY2019Q1	us-gaap	Paid In Kind Interest PaidInKindInterest	49000	USD
CY2020Q1	us-gaap	Paid In Kind Interest PaidInKindInterest	379000	USD
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1169000	USD
CY2020Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1112000	USD
CY2019Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	2410000	USD
CY2019Q1	us-gaap	Interest Expense InterestExpense	273000	USD
CY2020Q1	us-gaap	Interest Expense InterestExpense	761000	USD
CY2019Q1	us-gaap	Interest Paid Net InterestPaidNet	224000	USD
CY2020Q1	us-gaap	Interest Paid Net InterestPaidNet	382000	USD
CY2019Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	2493000	USD
CY2020Q1	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	1473000	USD
CY2019Q4	us-gaap	Inventory Net InventoryNet	3444000	USD
CY2020Q1	us-gaap	Inventory Net InventoryNet	3611000	USD
CY2019Q4	us-gaap	Inventory Raw Materials And Supplies Net Of Reserves InventoryRawMaterialsAndSuppliesNetOfReserves	951000	USD
CY2020Q1	us-gaap	Inventory Raw Materials And Supplies Net Of Reserves InventoryRawMaterialsAndSuppliesNetOfReserves	2138000	USD
CY2019Q4	us-gaap	Liabilities Liabilities	26594000	USD
CY2020Q1	us-gaap	Liabilities Liabilities	23315000	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	30208000	USD
CY2020Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	19102000	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	26367000	USD
CY2020Q1	us-gaap	Liabilities Current LiabilitiesCurrent	23188000	USD
CY2019Q4	us-gaap	Long Term Debt LongTermDebt	20085000	USD
CY2020Q1	us-gaap	Long Term Debt LongTermDebt	16969000	USD
CY2019Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	20085000	USD
CY2020Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	16969000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	10859000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1135000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6552000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-8032000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-7852000	USD
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	-7665000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-10510000	USD
CY2019Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1662000	USD
CY2020Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-743000	USD
CY2019Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-6185000	USD
CY2020Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-9762000	USD
CY2019Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	44000	USD
CY2020Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	0	USD
CY2020Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2019Q1	us-gaap	Proceeds From Issuance Of Secured Debt ProceedsFromIssuanceOfSecuredDebt	19207000	USD
CY2019Q1	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	0	USD
CY2020Q1	us-gaap	Proceeds From Issuance Of Secured Debt ProceedsFromIssuanceOfSecuredDebt	0	USD
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.04
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	4356	USD
CY2020Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	7368000	USD
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.42
CY2020Q1	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	761000	USD
CY2019Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	54000	USD
CY2020Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2360000	USD
CY2019Q1	us-gaap	Profit Loss ProfitLoss	-7852000	USD
CY2020Q1	us-gaap	Profit Loss ProfitLoss	-10510000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1950000	USD
CY2020Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2120000	USD
CY2019Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	USD
CY2020Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	958000	USD
CY2019Q1	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	0	USD
CY2020Q1	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	2156000	USD
CY2019Q1	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	10812000	USD
CY2020Q1	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	2100000	USD
CY2019Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2100000	USD
CY2020Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2674000	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-102577000	USD
CY2020Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-113087000	USD
CY2019Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1853000	USD
CY2020Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1136000	USD
CY2020Q1	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	445000	USD
CY2020Q1	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P9M
CY2020Q1	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P1Y
CY2020Q1	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P1Y
CY2020Q1	us-gaap	Revenue Remaining Performance Obligation Percentage RevenueRemainingPerformanceObligationPercentage	0.58
CY2020Q1	us-gaap	Revenue Remaining Performance Obligation Percentage RevenueRemainingPerformanceObligationPercentage	0.39
CY2020Q1	us-gaap	Revenue Remaining Performance Obligation Percentage RevenueRemainingPerformanceObligationPercentage	0.03
CY2019Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	4791000	USD
CY2019Q1	us-gaap	Share Based Compensation ShareBasedCompensation	289000	USD
CY2020Q1	us-gaap	Share Based Compensation ShareBasedCompensation	328000	USD
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.670
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.700
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.025
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.014
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	0	USD
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	131000	shares
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1148000	shares
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	33	USD
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1743000	shares
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2760000	shares
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.73
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.78
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	0	USD
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	883000	shares
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	6.03
CY2020Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.00
CY2020Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	5.57
CY2020Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.04
CY2019Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P4Y10M24D
CY2020Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y0M3D
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y2M12D
CY2020Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y10M9D
CY2020Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P7Y9M14D
CY2020Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
CY2019Q2	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	103000	USD
CY2019Q4	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	39000	USD
CY2019Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	2410000	USD
CY2019Q4	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	8550000	USD
CY2019Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	54000	USD
CY2019Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	11000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	10137000	USD
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	5870000	USD
CY2019Q2	us-gaap	Stockholders Equity StockholdersEquity	-1345000	USD
CY2019Q3	us-gaap	Stockholders Equity StockholdersEquity	-7379000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	3614000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	-4213000	USD
CY2019Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	10211000	shares
CY2020Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	35569000	shares

Files In Submission

Name	View Source	Status
0001411690-20-000011-index-headers.html	Edgar Link	pending
0001411690-20-000011-index.html	Edgar Link	pending
0001411690-20-000011.txt	Edgar Link	pending
0001411690-20-000011-xbrl.zip	Edgar Link	pending
bngo-20200331.xml	Edgar Link	completed
bngo-20200331.xsd	Edgar Link	pending
bngo-20200331x10q.htm	Edgar Link	pending
bngo-20200331xexx311.htm	Edgar Link	pending
bngo-20200331xexx321.htm	Edgar Link	pending
bngo-20200331_cal.xml	Edgar Link	unprocessable
bngo-20200331_def.xml	Edgar Link	unprocessable
bngo-20200331_lab.xml	Edgar Link	unprocessable
bngo-20200331_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BNGO
Bionano Genomics, Inc. Stock $bngo

2020 Q1 Form 10-Q Financial Statement

#000141169020000011 Filed on June 18, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BNGO Bionano Genomics, Inc. Stock $bngo

2020 Q1 Form 10-Q Financial Statement

#000141169020000011 Filed on June 18, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BNGO
Bionano Genomics, Inc. Stock $bngo